Pharmaceutical and medical device industry groups urged the FDA Nov. 9 to revamp its policies on communications about unapproved, or off-label, uses of products.
The comments were made at a Food and Drug Administration meeting held to obtain input on the policies. FDA Commissioner Robert Califf said at the meeting that “off-label use is associated with more adverse events” and the agency is seeking input to ensure that its policies protect the public health.
Biopharmaceutical companies have been pushing in recent years to loosen what they see as overly burdensome and unclear FDA regulations on the types of product information they can discuss with doctors and other health professionals. Meanwhile, recent court cases challenging the constitutionality of the agency’s off-label promotion regulations have raised doubts about whether the federal government can continue to restrict manufacturers from sharing truthful information about the off-label uses of drugs and medical devices.
The FDA should issue new guidance or regulations to update its current policies, said representatives from the Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Innovation Organization (BIO) and the Advanced Medical Technology Association (AdvaMed). Among other things, they said payers need off-label information in order to make decisions about coverage and ensure patients have access to the treatments they need.
John Kamp, executive director of the Coalition for Healthcare Communication in New York, told me Nov. 7 in advance of the meeting he expects the FDA will release a draft guidance on off-label communications “fairly soon.”
“I think they’ll probably focus on” Section 114 of the Food and Drug Administration Modernization Act of 1997 (FDAMA) in the draft guidance, Kamp told Bloomberg BNA. Section 114 required the FDA to give more guidance on discussion with payers.
If the FDA issues draft guidance on Section 114, “it will open up the discussion with payers,” Kamp said. “The FDA either has to act or they have to let the courts take the initiative. I think it’s time for FDA to act.”
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)